Janus Kinase Inhibitor Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis. To Have A Snippet Of The Report, Request Sample: https://www.coherentmarketinsights.com/insight/request-sample/2553 Janus Kinase Inhibitor Market Drivers Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period. Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA). Janus Kinase Inhibitor Market Regional Analysis The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period. Report includes chapters which deeply display the following deliverable about industry : • Janus Kinase Inhibitor Market Research Objective and Assumption • Janus Kinase Inhibitor Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Janus Kinase Inhibitor Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Janus Kinase Inhibitor Market, By Regions • Janus Kinase Inhibitor Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Janus Kinase Inhibitor Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Janus Kinase Inhibitor Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Janus Kinase Inhibitor Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Janus Kinase Inhibitor Market Key Players Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation. Janus Kinase Inhibitor Market Taxonomy The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions. By Drugs • Baricitinib • Tofacitinib • Ruxolitinib • Pipeline drugs - Peficitinib By Indication • Rheumatoid arthritis • Psoriatic arthritis • Systemic lupus erythematosus • Others Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoinginsight/janus-kinase-inhibitor-market-2553 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling.
© Copyright 2024 Paperzz
